Protocol Review and Monitoring Committee


Siteman Cancer Center’s Protocol Review and Monitoring Committee (PRMC) reviews all cancer-related clinical research studies involving human subjects to ensure that they are scientifically and statistically sound, appropriately designed, feasible for completion based on Siteman’s patient population and existing clinical trials portfolio, and in compliance with NIH guidelines for clinical trials, including monitoring for accrual and undue toxicity.

The PRMC is a multidisciplinary committee drawing on expertise from many departments involved with cancer research that is charged with providing scientific peer-review for all cancer research studies conducted under the auspices of Siteman including, but not limited to, institutional, industrial, and national cooperative group studies; ensuring proper study design; reviewing all active trials under its purview for renewal/termination; and reviewing accrual in all active cancer research trials.  PRMC meets three times each month to evaluate all newly submitted cancer-related research studies proposed for activation at Siteman.

The PRMC reviews all active cancer research studies on an ongoing basis by assessing progress at regular intervals. All protocols are renewed through the PRMC until permanently closed to accrual with all participants off active intervention. PRMC reviews all protocol revisions until the study is closed with PRMC, at which point no further reviews are required.



Co-chairs: Megan Jacoby, MD, PhD; Julie Margenthaler, MD; Cliff Robinson, MD; Brad Kahl, MD; and Yikyung Park, ScD

Stephanie L Myles, Mgr Clinical Trials
[email protected]